Secukinumab: Rapid Efficacy in  Psoriasis After Primary Failure With Ustekinumab and Adalimumab

Aline Lissa Okita; Tatiane Benini; Denise Reis Longhi

doi:10.5826/dpc.1004a102

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab

Authors

Aline Lissa Okita Department of Dermatology, Universidade de Mogi das Cruzes, São Paulo, Brazil
Tatiane Benini Department of Dermatology, Universidade de Mogi das Cruzes, São Paulo, Brazil
Denise Reis Longhi Department of Dermatology, Universidade de Mogi das Cruzes, São Paulo, Brazil

Keywords:

severe psoriasis, biologics, secukinumab, adalimumab, ustekinumab

References

Morgado-Carrasco D, Riera-Monroig J, Fustà-Novell X, Alsina Gibert M. Response to secukinumab after treatment failure with ustekinumab in 6 patients with plaque psoriasis. Actas Dermosifiliogr. 2018;109(6):565-567. DOI: 10.1016/j.ad.2017.07.019. PMID: 29169562.

Warren RB, Barker J, Burden AD, et al. Secukinumab has demonstrated efficacy and safety in hard-to-treat anti–tumor necrosis factor α failure patients from the United Kingdom and Republic of Ireland: Results of the SIGNATURE study. J Am Acad Dermatol. 2018;79(3 Suppl 1): AB256. Poster Abstract. DOI: https://doi.org/10.1016/j.jaad.2018.05.1018.

Magnano M, Loi C, Patrizi A, et al. Secukinumab in multi-failure psoriatic patients: the last hope? J Dermatolog, Treat. 2018;29(6):583–585. DOI: 10.1080/09546634.2018.1427206.PMID: 29334270.

Pelechas E, Memi T, Voulgari PV, Drosos AA. A case of recalcitrant psoriatic arthritis to tnf inhibitors improved after administration of secukinumab, an IL-17A inhibitor. Rheumatol Ther. 2017;4(2):509–513. DOI:10.1007/s40744-017-0084-0. PMID: 29022197.